AERAMI THERAPEUTICS LOGO-VERTICAL- COLOR.png
Aerami Therapeutics to Present at Biotech Showcase™ 2023 during the 41st Annual J.P. Morgan Healthcare Conference Week
January 05, 2023 09:00 ET | Aerami Therapeutics Inc
DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary...
AERAMI THERAPEUTICS LOGO-VERTICAL- COLOR.png
Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901 (inhaled imatinib), a Critical Milestone Toward the Planned Initiation of a Phase 2 Trial in Pulmonary Arterial Hypertension (PAH) During the First Half of 2023
December 21, 2022 08:01 ET | Aerami Therapeutics Inc
AER-901 (inhaled imatinib), a potential reverse-remodeling therapy, is being developed to address unmet need for PAH treatments that target pulmonary vascular remodeling while supporting ease-of-use...
LisaYanez
Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer
December 21, 2022 08:00 ET | Aerami Therapeutics Inc
Lisa Yañez Incoming Chief Executive OfficerAerami Therapeutics DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics Holdings, Inc (“Aerami”), a clinical-stage biopharmaceutical...
AERAMI THERAPEUTICS LOGO-VERTICAL- COLOR.png
Aerami Therapeutics Appoints Lisa Yañez as Chief Operating Officer
June 16, 2022 09:00 ET | Aerami Therapeutics Inc
DURHAM, N.C., June 16, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (the “Company”), a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and other...
AERAMI THERAPEUTICS LOGO-VERTICAL- COLOR.png
Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension
August 25, 2021 09:00 ET | Aerami Therapeutics Inc
Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifyingDosing of patients in Phase 1 trial is...
AERAMI THERAPEUTICS LOGO-VERTICAL- COLOR.png
Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China
February 09, 2021 09:00 ET | Aerami Therapeutics Inc
DURHAM, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company developing inhaled therapies to treat severe...